The integrated use of pharmacokinetic and pharmacodynamic models for the definition of breakpoints

Infection, Supplement

Volumn 33, Issue 2, 2005, Pages 29-35

  Stass, H ^a   Dalhoff, A ^b  

^a BAYER PHARMA AG   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; CREATININE; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ALBUMIN BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY HEIGHT; COMMUNITY ACQUIRED PNEUMONIA; CREATININE CLEARANCE; FEMALE; GENDER; HUMAN; HUMAN EXPERIMENT; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NORMAL HUMAN; PHARMACODYNAMICS; POPULATION MODEL; PREDICTION; PROBABILITY; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONTROLLED STUDY; COVARIANCE; CREATININE BLOOD LEVEL; DATA ANALYSIS; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG TREATMENT FAILURE; EVALUATION; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; MAJOR CLINICAL STUDY; PARAMETER; POPULATION RESEARCH; RISK ASSESSMENT;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; BODY HEIGHT; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MONTE CARLO METHOD; QUINOLINES; SEX CHARACTERISTICS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME;

EID: 31444453725     PISSN: 01732129     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-005-8205-z     Document Type: Article

References (29)

1. Lynch JPI, Martinez FJ: Community acquired pneumonia. Curr Opin Pulm Med 1998;4:162-172.
2. Garau J: Clinical failures: the tip of the iceberg? Respir Med 2001; 95(Suppl. A): 5-11.
3. Garau J: Treatment of drug resistant pneumococcal pneumonia. Lancet Infect Dis 2002; 2: 404-415.
4. Kerkoven van D, Peetermans WE, Verbist L, Verhaegen JJ: Break-through pneumococcal bacteremia in patients treated with clarithromycin or oral β-lactams. J Antimicrob Chemother 2003; 51: 91-696.
5. Guay DRP: Treatment of bacterial skin and skin structure infections. Expert Opin Parmacother 2003; 4: 1259-1275.
6. Talan DA, Abrahamian FM, Moran GJ, Citron DM, Tan JO, Goldstein EJC: Clinical presentation and bacteriological analysis of infected human bites in patients presenting to emergency departments. Clin Infect Dis 2003; 37: 1481-1489.
7. Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm DF, Bradley JS: Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine, and skin and soft tissue infections in pediatric patients. Eur J Clin Microbiol Infect Dis 2004; 23: 445-455.
8. Hoban DJ, Felmingham D: The PROTEKT surveillance study: antimicrobial susceptibility of Haemophilus influenzae and Moraxella catarrhalis from community acquired respiratory tract infections. J Antimicrob Chemother 2002; 50 (Suppl., S1): 49-59.
9. Sadaba B, Azana JA, Campanero, Garcia-Quetglas E: Relationship between pharmacokinetics and pharmacodynamics of β-lactams and outcome. Clin Microbiol Infect 2004; 10: 990-998.
10. Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ: The importance of pharmacokinetic/pharmacodynamics surrogate markers to outcome. Clin Pharmacokinet 1995; 28: 143-160.
11. Dalhoff A, Ullmann U: Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models. Eur J Clin Microbiol Infect Dis 1990; 8: 479-487.
12. Andes D, Craig WA: Animal model pharmacokinetics and pharmacodynamics: critical review. J Antimicrob Agents 2002; 19: 261-268.
13. Greenwood D: In vitro veritas? Antimicrobial susceptibility tests and their clinical relevance. J Infect Dis 1981; 144: 380-385.
14. Ambrose PG, Quintiliani R: Limitations of single point pharmacodynamics analysis. Pediatr Infect Dis 2000; 19: 769.
15. Siefert HM, Kohlsdorfer C, Steinke W, Witt A: Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats. J Antimicrob Chemother 1999; 43 (Suppl. B): 61-67.
16. Bayer AG, data on file, 2000.
17. Zhanel GG, Palatnick L, Nichol KA, Bellyou T, Low DE, Hoban DJ: Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organisms Susceptiility study, 1997 to 2002. Antimicrob Agents Chemother 2003; 47: 1867-1874.
18. Canton R, Morosini M, Enright MC, Morissey I: Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant Streptococcus pneumoniae: data from the global PROTEKT surveillance programme. J Antimicrob Chemother 2003; 52: 944-952.
19. Jones ME, Karlowsky JA, Draghi DC, Thornsberry C, Sahm D, Nathwani D: Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. Int J Antimicrob Agents 2003; 22: 406-419.
20. Cockroft DN, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
21. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-1081.
22. Pickerill KE: Comparison of the fluoroquinolones based on pharmacokinetic and pharmacodynamic parameters. Pharmacotherapy 2000; 20: 417-428.
23. Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF: Pharmacodynamics of fluoroquinolones against Streptococcus pneumonias: analysis of phase III clinical trials. Antimicrob Agents Chemother 2001; 45: 2793-2797.
24. Rombout F: Investigation on population pharmacokinetics of moxifloxacin (BAY 12-8039), a multi study evaluation using data from studies 101, 102, 103, 104, 105, 107, 108, 110, 111, 113, 115, 117, 120, 123, 132, 133, 135, 136, 137, 139, 141, 142, 143, 144, 146, 148, 149, 154, 155. 156, 157 by noncompartmental mixed effect modelling. Report-No. PH-28008.
25. Woodcock JM, Andrews LM, Boswell AF, Brenwald NP, Wise R: In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41: 101-106.
26. Siefert HM, Domdey-Bette A, Henninger K, Hucke F, Kohlsdorfer C, Stass HH: Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother 1999; 43 (Suppl.B): 69-76.
27. Torres A, Muir JF, Corris P, Kubin R, Duprat-Lomon I, Sagnier PP, Höffken G: Effectiveness of oral moxifloxacin in standard first-line therapy in community-acquired pneumonia. Eur Respir J 2003; 21: 135-143.
28. Dalhoff A, Schmitz FJ: In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 2003; 22: 203-221.
29. Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl RN, Natarajan J, Corrado M: Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279: 125-129.